Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.

Humans Carcinoma, Hepatocellular / diagnostic imaging Liver Neoplasms / diagnostic imaging Consensus Contrast Media Gadolinium DTPA Magnetic Resonance Imaging / methods Magnetic Resonance Spectroscopy Patient Care Team

Gadoxetic acid Hepatocellular carcinoma Magnetic resonance imaging

Journal

European radiology

ISSN: 1432-1084

Titre abrégé: Eur Radiol

Pays: Germany

ID NLM: 9114774

Informations de publication

Date de publication:
Dec 2023

Historique:

received: 03 01 2023

accepted: 23 05 2023

revised: 15 05 2023

medline: 27 11 2023

pubmed: 13 7 2023

entrez: 13 7 2023

Statut: ppublish

Résumé

The 10th Global Forum for Liver Magnetic Resonance Imaging was held in October 2021. The themes of the presentations and discussions at this Forum are described in detail in the review by Taouli et al (2023). The focus of this second manuscript developed from the Forum is on multidisciplinary tumor board perspectives in hepatocellular carcinoma (HCC) management: how to approach early-, mid-, and late-stage management from the perspectives of a liver surgeon, an interventional radiologist, and an oncologist. The manuscript also includes a panel discussion by multidisciplinary experts on three selected cases that explore challenging aspects of HCC management. CLINICAL RELEVANCE STATEMENT: This review highlights the importance of a multidisciplinary team approach in liver cancer patients and includes the perspectives of a liver surgeon, an interventional radiologist, and an oncologist, including illustrative case studies. KEY POINTS: • A liver surgeon, interventional radiologist, and oncologist presented their perspectives on the treatment of early-, mid-, and late-stage HCC. • Different perspectives on HCC management between specialties emphasize the importance of multidisciplinary tumor boards. • A multidisciplinary faculty discussed challenging aspects of HCC management, as highlighted by three case studies.

Identifiants

DOI: 10.1007/s00330-023-09919-z PMID: 37439935 PMC: PMC10667403

pubmed: 37439935

doi: 10.1007/s00330-023-09919-z

pii: 10.1007/s00330-023-09919-z

pmc: PMC10667403

doi:

Substances chimiques

Contrast Media 0

Gadolinium DTPA K2I13DR72L

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Pagination

9167-9181

Subventions

Organisme : Bayer

ID : AG

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338

pubmed: 10518312 doi: 10.1055/s-2007-1007122

Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6

pubmed: 33479224 doi: 10.1038/s41572-020-00240-3

Tabrizian P, Roayaie S, Schwartz ME (2014) Current management of hepatocellular carcinoma. World J Gastroenterol 20:10223–10237

pubmed: 25132740 pmcid: 4130831 doi: 10.3748/wjg.v20.i30.10223

Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955

pubmed: 25010665 doi: 10.1097/SLA.0000000000000710

Roayaie S, Jibara G, Tabrizian P et al (2015) The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62:440–451

Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236

European Association for the Study of the Liver (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943

doi: 10.1016/j.jhep.2011.12.001

Zhang T, Zhang L, Xu Y et al (2020) Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. Am J Cancer Res 10:1658–1667

pubmed: 32642282 pmcid: 7339264

Marron TU, Fiel MI, Hamon P et al (2022) Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7:219–229

pubmed: 35065058 pmcid: 9901534 doi: 10.1016/S2468-1253(21)00385-X

Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

pubmed: 8594428 doi: 10.1056/NEJM199603143341104

Sapisochin G, Goldaracena N, Laurence JM et al (2016) The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 64:2077–2088

Yao FY, Mehta N, Flemming J et al (2015) Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 61:1968–1977

Tabrizian P, Holzner ML, Mehta N et al (2022) Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg 157:779–788

pubmed: 35857294 pmcid: 9301590

DiNorcia J, Florman SS, Haydel B et al (2020) Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC Transplant Consortium. Ann Surg 271:616–624

pubmed: 30870180 doi: 10.1097/SLA.0000000000003253

Mehta N, Heimbach JK, Lee DH et al (2017) Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time "sweet spot". Transplant 101:2071–2078

doi: 10.1097/TP.0000000000001752

Halazun KJ, Patzer RE, Rana AA et al (2014) Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 60:1957–1962

Assalino M, Terraz S, Grat M et al (2020) Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int 33:567–575

pubmed: 31994238 doi: 10.1111/tri.13586

Vogel A, Martinelli E, ESMO Guidelines Committee (2021) Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 32:801–805

pubmed: 33716105 doi: 10.1016/j.annonc.2021.02.014

Edeline J, Garin E (2020) Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90…. J Hepatol 72:1046–1048

pubmed: 32276729 doi: 10.1016/j.jhep.2020.03.026

Kloeckner R, Galle PR, Bruix J (2021) Local and regional therapies for hepatocellular carcinoma. Hepatology 73(Suppl 1):137–149

Kallini JR, Gabr A, Kulik L, Salem R, Lewandowski RJ (2016) The utility of unilobar Technetium-99m macroaggregated albumin to predict pulmonary toxicity in bilobar hepatocellular carcinoma prior to Yttrium-90 radioembolization. J Vasc Interv Radiol 27:1453–1456

pubmed: 27566430 doi: 10.1016/j.jvir.2016.06.004

Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Brit J Cancer 111:255–264

pubmed: 24937669 pmcid: 4102934 doi: 10.1038/bjc.2014.199

Burrel M, Reig M, Forner A et al (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 56:1330–1335

pubmed: 22314428 doi: 10.1016/j.jhep.2012.01.008

Lobo L, Yakoub D, Picado O et al (2016) Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 39:1580–1588

pubmed: 27586657 doi: 10.1007/s00270-016-1426-y

Sangro B, Maini CL, Ettorre GM et al (2018) Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 45:1721–1730

pubmed: 29516130 pmcid: 6097757 doi: 10.1007/s00259-018-3968-5

Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL (2015) Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 4:16–25

pubmed: 26020026 doi: 10.1159/000343878

Venerito M, Pech M, Canbay A et al (2020) NEMESIS: noninferiority, individual-patient metaanalysis of selective internal radiation therapy with (90)Y resin microspheres versus sorafenib in advanced hepatocellular carcinoma. J Nucl Med 61:1736–1742

pubmed: 32358087 doi: 10.2967/jnumed.120.242933

Allard M-A, Sebagh M, Ruiz A et al (2015) Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol 63:83–92

pubmed: 25646884 doi: 10.1016/j.jhep.2015.01.023

Ricke J, Steffen IG, Bargellini I et al (2020) Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 2:100173

Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370

pubmed: 28620797 doi: 10.1007/s12072-017-9799-9

Zhang H, Zhang W, Jiang L, Chen Y (2022) Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 10:3

pubmed: 35000616 pmcid: 8744248 doi: 10.1186/s40364-021-00350-4

Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382:1894–1905

pubmed: 32402160 doi: 10.1056/NEJMoa1915745

Finn RS, Qin S, Ikeda M et al (2021) IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 39:267–267

doi: 10.1200/JCO.2021.39.3_suppl.267

Gordan JD, Kennedy EB, Abou-Alfa GK et al (2020) Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol 38:4317–4345

pubmed: 33197225 doi: 10.1200/JCO.20.02672

Fulgenzi CAM, Cheon J, D'Alessio A et al (2022) Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study. Eur J Cancer 175:204–213

pubmed: 36148739 doi: 10.1016/j.ejca.2022.08.024

Sharma R, Pillai A, Marron TU et al (2022) Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 6:1776–1785

pubmed: 35481940 pmcid: 9234627 doi: 10.1002/hep4.1927

Fulgenzi CAM, D'Alessio A, Ogunbiyi O et al (2022) Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 31:681–691

pubmed: 35507361 doi: 10.1080/13543784.2022.2072726

Shek D, Read SA, Nagrial A et al (2021) Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. Oncologist 26:e1216–e1225

pubmed: 33818870 pmcid: 8265367 doi: 10.1002/onco.13776

Finn RS, Kudo M, Merle P et al LBA34 - Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Presented at: ESMO 2022, September 10, 2022; Paris, France. S808-S869

Kelley RK, Rimassa L, Cheng AL et al (2022) Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 23:995–1008

pubmed: 35798016 doi: 10.1016/S1470-2045(22)00326-6

Qin S, Chan LS, Gu S et al LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Presented at: ESMO 2022, September 10, 2022; Paris, France. S808-S869

Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1(8)

Qin S, Kudo M, Meyer T et al LBA36 - Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Presented at: ESMO 2022, September 10, 2022; Paris, France. S808-S869

Fulgenzi CAM, D'Alessio A, Airoldi C et al (2022) Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. Eur J Cancer 174:57–67.

pubmed: 35970037 doi: 10.1016/j.ejca.2022.06.058

Pinato DJ, Murray SM, Forner A et al (2021) Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 9:e003311

pubmed: 34593621 pmcid: 8487214 doi: 10.1136/jitc-2021-003311

Marinelli B, Kim E, D'Alessio A et al (2022) Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 10:e004205

pubmed: 35710293 pmcid: 9204420 doi: 10.1136/jitc-2021-004205

Rimassa L, Danesi R, Pressiani T, Merle P (2019) Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 77:20–28

pubmed: 31195212 doi: 10.1016/j.ctrv.2019.05.004

Cui T, Liu Y, Wang J, Liu L (2020) Adverse effects of immune-checkpoint inhibitors in hepatocellular carcinoma. OncoTargets Ther 13:11725–11740

doi: 10.2147/OTT.S279858

Fessas P, Possamai LA, Clark J et al (2020) Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 159:167–177

pubmed: 31646612 doi: 10.1111/imm.13141

Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19:151–172

pubmed: 34764464 doi: 10.1038/s41571-021-00573-2

Pinato DJ, Guerra N, Fessas P et al (2020) Immune-based therapies for hepatocellular carcinoma. Oncogene 39:3620–3637

pubmed: 32157213 pmcid: 7190571 doi: 10.1038/s41388-020-1249-9

Pinato DJ, Marron TU, Mishra-Kalyani PS et al (2021) Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 157:140–152

pubmed: 34508996 doi: 10.1016/j.ejca.2021.08.020

Pinato DJ, Fessas P, Sapisochin G, Marron TU (2021) Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma. Hepatology 74:483–490

Bruix J, Takayama T, Mazzaferro V et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16:1344–1354

pubmed: 26361969 doi: 10.1016/S1470-2045(15)00198-9

Cheng AL, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862–873

pubmed: 34902530 doi: 10.1016/j.jhep.2021.11.030

D'Alessio A, Fulgenzi CAM, Nishida N et al (2022) Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology 76:1000–1012

pubmed: 35313048 doi: 10.1002/hep.32468

Kudo M (2021) A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer 10:539–544

pubmed: 34950177 pmcid: 8647118 doi: 10.1159/000519749

Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A (2022) Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Rep 4:100498

pubmed: 35860434 pmcid: 9289870 doi: 10.1016/j.jhepr.2022.100498